Institute Curie - Centre de Lutte Contre Le Cancer CLCC de Paris

Paris 75005

0 studies enrolling now · 1 studies all time

What they study most

HER2 Positive Breast Cancer

Studies at this site

• A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer — Completed